Proxima Capital Management’s Trinity Biotech TRIB Stock Holding History

Proxima Capital Management’s Portfolio TRIB Stock Details TRIB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q4	–	Sell	-5,875	Closed	-$165K	–	39
2017 Q3	$165K	Hold	5,875	–	–	0.09%	36
2017 Q2	$176K	Hold	5,875	–	–	0.1%	38
2017 Q1	$175K	Hold	5,875	–	–	0.11%	35
2016 Q4	$203K	Hold	5,875	–	–	0.1%	34
2016 Q3	$388K	Sell	5,875 -925	-14%	-$57.6K	0.18%	34
2016 Q2	$386K	Hold	6,800	–	–	0.15%	35
2016 Q1	$396K	Buy	+6,800	New	+$361K	0.15%	36

Other funds holding TRIB

PIM

Paradice Investment Management Denver, Colorado $532M AUM 29.6% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

Heartland Advisors Milwaukee, Wisconsin $1.96B AUM 28.26% 1-Year Est. Return

Russell Investments Group London, United Kingdom $93.1B AUM 28.26% 1-Year Est. Return

LAM

Lapides Asset Management Greenwich, Connecticut $153M AUM 9.03% 1-Year Est. Return

Boston Partners Boston, Massachusetts $95.5B AUM 28.4% 1-Year Est. Return

FWSM

First Wilshire Securities Management Pasadena, California $444M AUM 42.88% 1-Year Est. Return

Senvest Management New York $3.01B AUM 35.7% 1-Year Est. Return

22NW LP Seattle, Washington $146M AUM 29.83% 1-Year Est. Return

SCM

Stonehill Capital Management New York $197M AUM 96.45% 1-Year Est. Return

Proxima Capital Management's TRIB Position: Q4 2017 in Review

Proxima Capital Management sold out of Trinity Biotech (TRIB) in Q4 2017, closing a stake of 5,875 shares — an estimated $165K sold.

Proxima Capital Management first reported a position in TRIB in Q1 2016 and held it in 7 quarters. The position peaked at $396K in Q1 2016. 48 funds tracked by Wall St. Rank hold TRIB as of Q4 2017.

Proxima Capital Management reported no remaining Trinity Biotech position as of Q4 2017 after selling out during the quarter.
Proxima Capital Management sold 5,875 Trinity Biotech shares in Q4 2017, an estimated $165K.
Proxima Capital Management first reported a position in Trinity Biotech in Q1 2016 and held it in 7 quarters.
Proxima Capital Management's Trinity Biotech position peaked at $396K in Q1 2016.
48 funds tracked by Wall St. Rank held Trinity Biotech as of Q4 2017.

Based on Proxima Capital Management's 13F filing for Q4 2017, filed 14 Feb 2018.